Kalyan C. Nagulapalli Venkata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kalyan C. Nagulapalli Venkata has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Anupam Bishayee
Department of Pharmacology, College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, USA
6 shared publications - Nicos A. Petasis
Department of Chemistry and Loker Hydrocarbon Research Institute, University of Southern California, Los Angeles, CA 90089, USA
6 shared publications - Dongyun Yang
Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
4 shared publications David O. Rosenberg
3 shared publicationsPierre O. Bohanes
3 shared publicationsRobert D. Ladner
3 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (9) , 1987
Targeting the 3C Protease of Hepatitis A Virus Subgenotype IB: Virtual Screening and Identification of Potent Lead Candidates
Hepatitis A virus (HAV) infection remains a global public health concern in both developing and developed countries. In the present study, we identified anti-HAV drugs, using AutoDock Vina Modeling software, and evaluated the compounds in vitro. Following cytotoxicity for Huh7 cells, 5 out of 10 compounds were selected. We evaluated effective HAV 3C protease inhibitors with activity against both HAV genotype IB HM175/18f and HAV genotype IIIA HA11-1299-infected human hepatoma cells. Among the five compounds, we identified only one (KCN-A-12), which had an inhibitory effect on both HAV genotype IB HM175/18f and HAV genotype IIIA HA11-1299 replication in human hepatoma Huh7 cells. KCN-A-12 has more effective inhibitory effects on the replication of HAV genotype IB HM175/18f than that of HAV genotype IIIA HA11-1299. This difference may be attributable to the fact that our discovery system depends on crystal structures from HAV 3C protease based on the HAV genotype IB HM175 strain. In conclusion, we observed that KCN-A-12 was able to inhibit HAV replication. In silico screening for HAV 3C protease inhibitors may be useful for further discovery of anti-HAV drugs.
- 8 September 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (9) , 1987
Open AccessTargeting the 3C Protease of Hepatitis A Virus Subgenotype IB: Virtual Screening and Identification of Potent Lead Candidates
Hepatitis A virus (HAV) infection remains a global public health concern in both developing and developed countries. In the present study, we identified anti-HAV drugs, using AutoDock Vina Modeling software, and evaluated the compounds in vitro. Following cytotoxicity for Huh7 cells, 5 out of 10 compounds were selected. We evaluated effective HAV 3C protease inhibitors with activity against both HAV genotype IB HM175/18f and HAV genotype IIIA HA11-1299-infected human hepatoma cells. Among the five compounds, we identified only one (KCN-A-12), which had an inhibitory effect on both HAV genotype IB HM175/18f and HAV genotype IIIA HA11-1299 replication in human hepatoma Huh7 cells. KCN-A-12 has more effective inhibitory effects on the replication of HAV genotype IB HM175/18f than that of HAV genotype IIIA HA11-1299. This difference may be attributable to the fact that our discovery system depends on crystal structures from HAV 3C protease based on the HAV genotype IB HM175 strain. In conclusion, we observed that KCN-A-12 was able to inhibit HAV replication. In silico screening for HAV 3C protease inhibitors may be useful for further discovery of anti-HAV drugs.
- 15 September 2023
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 15 (11) , 974-978
Assessing the utility of pre-course assessment and voluntary pre-work in two required integrated pharmacotherapy courses
- 15 September 2023
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 15 (11) , 974-978
Assessing the utility of pre-course assessment and voluntary pre-work in two required integrated pharmacotherapy courses
- Open Access
- 27 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (11) , 6044
Evaluation of Potential Anti-Hepatitis A Virus 3C Protease Inhibitors Using Molecular Docking
Hepatitis A virus (HAV) infection is a major cause of acute hepatitis worldwide and occasionally causes acute liver failure and can lead to death in the absence of liver transplantation. Although HAV vaccination is available, the prevalence of HAV vaccination is not adequate in some countries. Additionally, the improvements in public health reduced our immunity to HAV infection. These situations motivated us to develop potentially new anti-HAV therapeutic options. We carried out the in silico screening of anti-HAV compounds targeting the 3C protease enzyme using the Schrodinger Modeling software from the antiviral library of 25,000 compounds to evaluate anti-HAV 3C protease inhibitors. Additionally, in vitro studies were introduced to examine the inhibitory effects of HAV subgenomic replicon replication and HAV HA11-1299 genotype IIIA replication in hepatoma cell lines using luciferase assays and real-time RT-PCR. In silico studies enabled us to identify five lead candidates with optimal binding interactions in the active site of the target HAV 3C protease using the Schrodinger Glide program. In vitro studies substantiated our hypothesis from in silico findings. One of our lead compounds, Z10325150, showed 47% inhibitory effects on HAV genotype IB subgenomic replicon replication and 36% inhibitory effects on HAV genotype IIIA HA11-1299 replication in human hepatoma cell lines, with no cytotoxic effects at concentrations of 100 μg/mL. The effects of the combination therapy of Z10325150 and RNA-dependent RNA polymerase inhibitor, favipiravir on HAV genotype IB HM175 subgenomic replicon replication and HAV genotype IIIA HA11-1299 replication showed 64% and 48% inhibitory effects of HAV subgenomic replicon and HAV replication, respectively. We identified the HAV 3C protease inhibitor Z10325150 through in silico screening and confirmed the HAV replication inhibitory activity in human hepatocytes. Z10325150 may offer the potential for a useful HAV inhibitor in severe hepatitis A.
- 27 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (11) , 6044
Open AccessEvaluation of Potential Anti-Hepatitis A Virus 3C Protease Inhibitors Using Molecular Docking
Hepatitis A virus (HAV) infection is a major cause of acute hepatitis worldwide and occasionally causes acute liver failure and can lead to death in the absence of liver transplantation. Although HAV vaccination is available, the prevalence of HAV vaccination is not adequate in some countries. Additionally, the improvements in public health reduced our immunity to HAV infection. These situations motivated us to develop potentially new anti-HAV therapeutic options. We carried out the in silico screening of anti-HAV compounds targeting the 3C protease enzyme using the Schrodinger Modeling software from the antiviral library of 25,000 compounds to evaluate anti-HAV 3C protease inhibitors. Additionally, in vitro studies were introduced to examine the inhibitory effects of HAV subgenomic replicon replication and HAV HA11-1299 genotype IIIA replication in hepatoma cell lines using luciferase assays and real-time RT-PCR. In silico studies enabled us to identify five lead candidates with optimal binding interactions in the active site of the target HAV 3C protease using the Schrodinger Glide program. In vitro studies substantiated our hypothesis from in silico findings. One of our lead compounds, Z10325150, showed 47% inhibitory effects on HAV genotype IB subgenomic replicon replication and 36% inhibitory effects on HAV genotype IIIA HA11-1299 replication in human hepatoma cell lines, with no cytotoxic effects at concentrations of 100 μg/mL. The effects of the combination therapy of Z10325150 and RNA-dependent RNA polymerase inhibitor, favipiravir on HAV genotype IB HM175 subgenomic replicon replication and HAV genotype IIIA HA11-1299 replication showed 64% and 48% inhibitory effects of HAV subgenomic replicon and HAV replication, respectively. We identified the HAV 3C protease inhibitor Z10325150 through in silico screening and confirmed the HAV replication inhibitory activity in human hepatocytes. Z10325150 may offer the potential for a useful HAV inhibitor in severe hepatitis A.
- 1 December 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 225, 113747
Efforts towards the inhibitor design for New Delhi metallo-beta-lactamase (NDM-1)
- 1 December 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 225, 113747
Efforts towards the inhibitor design for New Delhi metallo-beta-lactamase (NDM-1)
- Open Access
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Impact of In‐person and Remote Class Attendance on Student Performance in a Required Course
Our University implemented many changes to ensure safe environment for all members of our community during the pandemic. The students were given the opportunity to choose between attending class sessions and taking exams in person (in the classroom) or remotely (from off‐campus locations). The impact of in‐person and remote synchronous class attendance on student performance is largely unknown thus our objective was to explore it. We tested the hypothesis that in‐person class attendance may have more beneficial effects on student performance than remote class attendance in a required course. We conducted a retrospective, quantitative study in Principles of Drug Action course, a required integrated pharmacology/medicinal chemistry course in Pharm.D. curriculum, traditionally offered exclusively in person. Mean overall scores on baseline knowledge test (a control for student background knowledge before entering Pharm.D. program), exams, individual quizzes, and total course performance were analyzed for students attending the class sessions in person and remotely (total of 88 and 50 students, respectively). In addition, lecture recording accessions were analyzed and compared. The student performances were analyzed using t‐test. Differences were considered significant if p<0.05. The mean overall performances on exams (78.2% vs. 72.7%, p<0.05) and course totals (81.6% vs. 77.4%, p<0.05), but not on individual quizzes (65.5% vs. 62.9%, p=0.43) were significantly higher for students attending class sessions in person versus those attending remotely. No difference was detected in the mean performances between these student groups on the baseline knowledge test. The students attending class sessions in person spent less time accessing the lecture recordings than those attending remotely (average 352 min vs. 525 min, respectively). In‐person class attendance led to better student performances on major course assessments and overall course grades compared to remote class attendance. These results suggest that in‐person classes may be more beneficial and impactful for student learning in this and possibly other courses and may be considered when making decisions about class attendance in the future.
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Open AccessImpact of In‐person and Remote Class Attendance on Student Performance in a Required Course
Our University implemented many changes to ensure safe environment for all members of our community during the pandemic. The students were given the opportunity to choose between attending class sessions and taking exams in person (in the classroom) or remotely (from off‐campus locations). The impact of in‐person and remote synchronous class attendance on student performance is largely unknown thus our objective was to explore it. We tested the hypothesis that in‐person class attendance may have more beneficial effects on student performance than remote class attendance in a required course. We conducted a retrospective, quantitative study in Principles of Drug Action course, a required integrated pharmacology/medicinal chemistry course in Pharm.D. curriculum, traditionally offered exclusively in person. Mean overall scores on baseline knowledge test (a control for student background knowledge before entering Pharm.D. program), exams, individual quizzes, and total course performance were analyzed for students attending the class sessions in person and remotely (total of 88 and 50 students, respectively). In addition, lecture recording accessions were analyzed and compared. The student performances were analyzed using t‐test. Differences were considered significant if p<0.05. The mean overall performances on exams (78.2% vs. 72.7%, p<0.05) and course totals (81.6% vs. 77.4%, p<0.05), but not on individual quizzes (65.5% vs. 62.9%, p=0.43) were significantly higher for students attending class sessions in person versus those attending remotely. No difference was detected in the mean performances between these student groups on the baseline knowledge test. The students attending class sessions in person spent less time accessing the lecture recordings than those attending remotely (average 352 min vs. 525 min, respectively). In‐person class attendance led to better student performances on major course assessments and overall course grades compared to remote class attendance. These results suggest that in‐person classes may be more beneficial and impactful for student learning in this and possibly other courses and may be considered when making decisions about class attendance in the future.
- Open Access
Momordicine-I, a Bitter Melon Bioactive Metabolite, Displays Anti-Tumor Activity in Head and Neck Cancer Involving c-Met and Downstream Signaling
Head and neck cancer (HNC) is one of the most aggressive cancers, and treatments are quite challenging due to the difficulty in early diagnosis, lack of effective chemotherapeutic drugs, adverse side effects and therapy resistance. We identified momordicine-I (M-I), a bioactive secondary metabolite in bitter melon (Momordica charantia), by performing liquid chromatography-high resolution electrospray ionization mass spectrometry (LC-HRESIMS) analysis. M-I inhibited human HNC cell (JHU022, JHU029, Cal27) viability in a dose-dependent manner without an apparent toxic effect on normal oral keratinocytes. Mechanistic studies showed that M-I inhibited c-Met and its downstream signaling molecules c-Myc, survivin, and cyclin D1 through the inactivation of STAT3 in HNC cells. We further observed that M-I was non-toxic and stable in mouse (male C57Bl/6) blood, and a favorable pharmacokinetics profile was observed after IP administration. M-I treatment reduced HNC xenograft tumor growth in nude mice and inhibited c-Met and downstream signaling. Thus, M-I has potential therapeutic implications against HNC.
Open AccessMomordicine-I, a Bitter Melon Bioactive Metabolite, Displays Anti-Tumor Activity in Head and Neck Cancer Involving c-Met and Downstream Signaling
Head and neck cancer (HNC) is one of the most aggressive cancers, and treatments are quite challenging due to the difficulty in early diagnosis, lack of effective chemotherapeutic drugs, adverse side effects and therapy resistance. We identified momordicine-I (M-I), a bioactive secondary metabolite in bitter melon (Momordica charantia), by performing liquid chromatography-high resolution electrospray ionization mass spectrometry (LC-HRESIMS) analysis. M-I inhibited human HNC cell (JHU022, JHU029, Cal27) viability in a dose-dependent manner without an apparent toxic effect on normal oral keratinocytes. Mechanistic studies showed that M-I inhibited c-Met and its downstream signaling molecules c-Myc, survivin, and cyclin D1 through the inactivation of STAT3 in HNC cells. We further observed that M-I was non-toxic and stable in mouse (male C57Bl/6) blood, and a favorable pharmacokinetics profile was observed after IP administration. M-I treatment reduced HNC xenograft tumor growth in nude mice and inhibited c-Met and downstream signaling. Thus, M-I has potential therapeutic implications against HNC.
- Top Cited PapersOpen Access
Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice
Pharmacists have access to a plethora of information related to drugs. Online compendia concerning top 200 prescribed drugs are readily-accessible, comparatively-easy to search. While these resources provide some information about the commonly prescribed drugs, they lack in furnishing in-depth knowledge to pharmacy students, pharmacists and other healthcare professionals. The aim of this paper is to present the relevant details of top 200 most prescribed drugs in the United States. The names and therapeutic classes of top 200 prescribed drugs were compiled from online resources. The pharmacological actions of drugs, any reported adverse reactions and black box warnings are collected from drug bank resources, such as AccessPharmacy and Lexicomp. The paper provides comprehensive information about top 200 prescribed drugs, which includes generic names, pharmacological action, route of administration and adverse reaction profile including black box warning when applicable. Overall, the drug list may serve as an easy access of ideas for pharmacists, researchers and other healthcare professionals interested in developing new strategies for treating patients with various ailments.
Top Cited PapersOpen AccessComprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice
Pharmacists have access to a plethora of information related to drugs. Online compendia concerning top 200 prescribed drugs are readily-accessible, comparatively-easy to search. While these resources provide some information about the commonly prescribed drugs, they lack in furnishing in-depth knowledge to pharmacy students, pharmacists and other healthcare professionals. The aim of this paper is to present the relevant details of top 200 most prescribed drugs in the United States. The names and therapeutic classes of top 200 prescribed drugs were compiled from online resources. The pharmacological actions of drugs, any reported adverse reactions and black box warnings are collected from drug bank resources, such as AccessPharmacy and Lexicomp. The paper provides comprehensive information about top 200 prescribed drugs, which includes generic names, pharmacological action, route of administration and adverse reaction profile including black box warning when applicable. Overall, the drug list may serve as an easy access of ideas for pharmacists, researchers and other healthcare professionals interested in developing new strategies for treating patients with various ailments.
- 4 January 2018
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 70 (2) , 164-175
Curcumin and Melanoma: From Chemistry to Medicine
Melanoma is the most deadly form of skin cancer, with about 48,000 deaths each year worldwide. Growing evidence suggests that individual nutrients or dietary patterns might have important roles in the prevention of melanoma. Considering that melanoma is a potentially life-threatening cancer, novel protective and adjuvant treatments are needed to improve its prognosis. Curcumin is a bioactive substance extracted from rhizome of Curcuma longa L. Its global market is expected to grow in the next few years, especially in the pharmaceutical industry, due to its numerous physiological and pharmacological properties. For this review, we collected the available data on the protective and therapeutic role of curcumin against melanoma. We also discuss the chemistry, dietary sources, bioavailability, and metabolism of curcumin, and the mechanisms of action of its potential anticancer effects at the molecular level. Current challenges and future directions for research are also critically discussed.
- 4 January 2018
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 70 (2) , 164-175
Curcumin and Melanoma: From Chemistry to Medicine
Melanoma is the most deadly form of skin cancer, with about 48,000 deaths each year worldwide. Growing evidence suggests that individual nutrients or dietary patterns might have important roles in the prevention of melanoma. Considering that melanoma is a potentially life-threatening cancer, novel protective and adjuvant treatments are needed to improve its prognosis. Curcumin is a bioactive substance extracted from rhizome of Curcuma longa L. Its global market is expected to grow in the next few years, especially in the pharmaceutical industry, due to its numerous physiological and pharmacological properties. For this review, we collected the available data on the protective and therapeutic role of curcumin against melanoma. We also discuss the chemistry, dietary sources, bioavailability, and metabolism of curcumin, and the mechanisms of action of its potential anticancer effects at the molecular level. Current challenges and future directions for research are also critically discussed.